Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in systemic lupus erythematosus
NL-OMON59142Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of belimumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in peripheral blood B-lineage cell composition and Change in lymph node B-lineage cell composition. Started Nov 2024; status: recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON59142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59142.